Ian C Scott, Ram Bajpai, Samantha L Hider, Toby Helliwell, Christian D Mallen, Sara Muller
{"title":"多发性风湿性关节炎患者肥胖与患者报告的结果测量之间的关系。","authors":"Ian C Scott, Ram Bajpai, Samantha L Hider, Toby Helliwell, Christian D Mallen, Sara Muller","doi":"10.1093/rap/rkae081","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To examine the association between obesity and patient-reported outcome measures (PROMs) in a primary care-based cohort of people with PMR.</p><p><strong>Methods: </strong>The PMR Cohort Study recruited people with incident PMR from 382 general practices. Self-completed questionnaires (0, 12, 24 months) captured a range of PROMs for pain, stiffness, anxiety, depression, fatigue, function and quality of life, alongside data on BMI. People were categorized as underweight/normal weight (BMI < 25kg/m<sup>2</sup>), overweight (25-29.99 kg/m<sup>2</sup>) or obese (≥30 kg/m<sup>2</sup>). Piecewise, multilevel, linear mixed-effects regression models examined relationships between BMI categories and PROMs over time, adjusting for confounding variables. Chi-squared tests examined the relationship between obesity and glucocorticoid persistence.</p><p><strong>Results: </strong>644 people with PMR were included. At baseline, 33.9% were normal/underweight, 40.6% overweight and 25.5% obese. Compared with normal/underweight people, those with obesity had significantly worse scores for the following: pain and stiffness at 12 months; fatigue at 12 and 24 months; depression at baseline; physical function at all time points; and quality of life at baseline and 12 months. They also had significantly smaller improvements in stiffness (1.13 units on an 11-point numeric rating scale; <i>P </i>=<i> </i>0.001) and physical function (0.14 units measured using the modified Health Assessment Questionnaire; <i>P </i>=<i> </i>0.025) between 0 and 12 months. BMI categories did not relate to persistent glucocorticoid use at 12 months (<i>P </i>=<i> </i>0.110) or 24 months (<i>P </i>=<i> </i>0.166).</p><p><strong>Conclusion: </strong>Obesity associates with poorer outcomes for a range of PROMs in people with PMR. Consideration should be given to providing weight management support to people with PMR and obesity.</p>","PeriodicalId":21350,"journal":{"name":"Rheumatology Advances in Practice","volume":"8 3","pages":"rkae081"},"PeriodicalIF":2.1000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239789/pdf/","citationCount":"0","resultStr":"{\"title\":\"The relationship between obesity and patient-reported outcome measures in people with polymyalgia rheumatica.\",\"authors\":\"Ian C Scott, Ram Bajpai, Samantha L Hider, Toby Helliwell, Christian D Mallen, Sara Muller\",\"doi\":\"10.1093/rap/rkae081\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To examine the association between obesity and patient-reported outcome measures (PROMs) in a primary care-based cohort of people with PMR.</p><p><strong>Methods: </strong>The PMR Cohort Study recruited people with incident PMR from 382 general practices. Self-completed questionnaires (0, 12, 24 months) captured a range of PROMs for pain, stiffness, anxiety, depression, fatigue, function and quality of life, alongside data on BMI. People were categorized as underweight/normal weight (BMI < 25kg/m<sup>2</sup>), overweight (25-29.99 kg/m<sup>2</sup>) or obese (≥30 kg/m<sup>2</sup>). Piecewise, multilevel, linear mixed-effects regression models examined relationships between BMI categories and PROMs over time, adjusting for confounding variables. Chi-squared tests examined the relationship between obesity and glucocorticoid persistence.</p><p><strong>Results: </strong>644 people with PMR were included. At baseline, 33.9% were normal/underweight, 40.6% overweight and 25.5% obese. Compared with normal/underweight people, those with obesity had significantly worse scores for the following: pain and stiffness at 12 months; fatigue at 12 and 24 months; depression at baseline; physical function at all time points; and quality of life at baseline and 12 months. They also had significantly smaller improvements in stiffness (1.13 units on an 11-point numeric rating scale; <i>P </i>=<i> </i>0.001) and physical function (0.14 units measured using the modified Health Assessment Questionnaire; <i>P </i>=<i> </i>0.025) between 0 and 12 months. BMI categories did not relate to persistent glucocorticoid use at 12 months (<i>P </i>=<i> </i>0.110) or 24 months (<i>P </i>=<i> </i>0.166).</p><p><strong>Conclusion: </strong>Obesity associates with poorer outcomes for a range of PROMs in people with PMR. Consideration should be given to providing weight management support to people with PMR and obesity.</p>\",\"PeriodicalId\":21350,\"journal\":{\"name\":\"Rheumatology Advances in Practice\",\"volume\":\"8 3\",\"pages\":\"rkae081\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-07-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11239789/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology Advances in Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/rap/rkae081\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology Advances in Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/rap/rkae081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
The relationship between obesity and patient-reported outcome measures in people with polymyalgia rheumatica.
Objective: To examine the association between obesity and patient-reported outcome measures (PROMs) in a primary care-based cohort of people with PMR.
Methods: The PMR Cohort Study recruited people with incident PMR from 382 general practices. Self-completed questionnaires (0, 12, 24 months) captured a range of PROMs for pain, stiffness, anxiety, depression, fatigue, function and quality of life, alongside data on BMI. People were categorized as underweight/normal weight (BMI < 25kg/m2), overweight (25-29.99 kg/m2) or obese (≥30 kg/m2). Piecewise, multilevel, linear mixed-effects regression models examined relationships between BMI categories and PROMs over time, adjusting for confounding variables. Chi-squared tests examined the relationship between obesity and glucocorticoid persistence.
Results: 644 people with PMR were included. At baseline, 33.9% were normal/underweight, 40.6% overweight and 25.5% obese. Compared with normal/underweight people, those with obesity had significantly worse scores for the following: pain and stiffness at 12 months; fatigue at 12 and 24 months; depression at baseline; physical function at all time points; and quality of life at baseline and 12 months. They also had significantly smaller improvements in stiffness (1.13 units on an 11-point numeric rating scale; P =0.001) and physical function (0.14 units measured using the modified Health Assessment Questionnaire; P =0.025) between 0 and 12 months. BMI categories did not relate to persistent glucocorticoid use at 12 months (P =0.110) or 24 months (P =0.166).
Conclusion: Obesity associates with poorer outcomes for a range of PROMs in people with PMR. Consideration should be given to providing weight management support to people with PMR and obesity.